BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Eluminex Reports Positive Phase 1 Results for EB-105 in Diabetic Macular Edema Patients

EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6R Improvements in Visual Acuity and Retinal Edema Observed at All Dose Levels No Safety Issues Observed...

June 10, 2025 | News

New Studies Presented at ERA 2025 Reinforce NEFECON®’s Early Intervention Value in IgA Nephropathy

Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust su...

June 09, 2025 | News

ASCO 2025 Showcases New Oncology Paradigms, From Breast Cancer Breakthroughs to AI-Led Precision Medicine

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting wasn’t just another scientific gathering and it was a seismic event that redrew ...

June 06, 2025 | Report

Innovent Secures Second NMPA Breakthrough Therapy Designation for IBI363 in Advanced Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

June 05, 2025 | News

Transgene and NEC Report Sustained Disease-Free Survival With TG4050 in Head and Neck Cancer at ASCO 2025

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (...

June 03, 2025 | News

Protagonist Therapeutics and Takeda Report Positive Phase 3 Results for Rusfertide in PV, Meeting All Primary and Secondary Endpoints

Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phleboto...

June 03, 2025 | News

Eisai’s DAYVIGO® Approved in China to Treat Insomnia, Targeting Over 170 Million Adults

Eisai Co., Ltd. announced that the in-house-discovered and developed orexin receptor antagonist DAYVIGO® (generic name: lemborexant) has been app...

May 29, 2025 | News

NICE Recommends CSL Vifor’s Sparsentan for Routine Use in Treating IgA Nephropathy in England

CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending tha...

May 26, 2025 | News

AnnJi Reports Promising Phase 1/2a Results for AJ201 in Rare Neuromuscular Disease SBMA

AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and r...

May 22, 2025 | News

AstraZeneca’s AIRSUPRA Cuts Severe Asthma Exacerbations by 47%, Redefines Mild Asthma Treatment Standard

AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone Full results published in th...

May 20, 2025 | News

Nordic Bioscience Launches nordicEndotrophin™ to Advance Risk Stratification and Monitoring in Fibrosis and Cancer

Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrop...

May 19, 2025 | News

Shanghai Ark Biopharmaceutical Announces Positive Phase II Results for AK3280 in Idiopathic Pulmonary Fibrosis

Shanghai Ark Biopharmaceutical Co., Ltd. announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of id...

May 16, 2025 | News

Gene Solutions Validates K-TRACK™ ctDNA Test as Prognostic Biomarker

Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is excited to announce the publication of a pioneering real-worl...

May 12, 2025 | News

Nutshell Therapeutics Receives FDA IND Clearance for First-in-Human Trial of NTS071 Targeting p53 Y220C Mutation

Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical ...

May 05, 2025 | News

Stay Connected